Smith & Nephew has acquired Ceterix® Orthopaedics for $50m as part of its strategy to invest in innovative technologies for unmet clinical needs.

The company has also agreed to pay up to $55m over the next five years, based on financial performance.

Based in the UK, Smith & Nephew company is engaged in manufacturing medical equipment. Ceterix® Orthopaedics is a US-based developer of surgical tools for arthroscopic procedures and the NovoStitch® Pro Meniscal Repair System.

Nordic Capital Fund IX has reached an agreement with Altor Fund III (Altor) to acquire a majority holding in Orchid Orthopedic Solutions (Orchid).

Financial terms of the deal have not been disclosed.

Based in the US, Orchid designs and manufactures implants for the orthopaedic market, while Nordic Capital, based in Europe, is a private equity investor with successful healthcare investments in North America.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

1315 Capital has acquired Biocoat as part of its growth-oriented strategy to enter the biomaterial coatings market for medical devices.

“The acquisition is intended to increase 1315 Capital’s business offering by making use of Biocoat’s differentiated technology.”

The acquisition is intended to increase 1315 Capital’s business offering by making use of Biocoat’s differentiated technology.

1315 Capital is engaged in providing expansion and growth capital to commercial-stage healthcare services, medical technology, and speciality pharmaceutical companies. Biocoat is involved in the development and licensing of biomaterial coatings for medical devices. Both companies are based in the US.

Abbott has acquired Cephea Valve Technologies by exercising its previously held option secured in 2015.

The acquisition of Cephea is part of Abbott’s strategy to develop comprehensive treatments for people with mitral valve disease and will help the company in maintaining its position in structural heart therapies.

Abbott is a global healthcare company engaged in conducting innovative research and manufactures products for human health. Cephea Valve Technologies is a privately held medical device company, which develops less-invasive heart valve replacement technology for people with mitral valve disease. Both companies are based in the US.